GE HealthCare Technologies Inc.(GEHC) Stock Research - Grey Stern Research
Loading...

GE HealthCare Technologies Inc. (GEHC) Stock Analysis

$80.67 (-2.17%)

GEHC Financial Performance


Use the table below to view GE HealthCare Technologies Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $82.46 -
52 Week Low $74.51 -
52 Week High $94.80 -
Market Cap $37.7 Billion 1/1
Gross Margin 43% 1/1
Profit Margin 14% 1/1
EBITDA margin 20% 1/1
Q4 - 2024 Revenue $5.3 Billion 1/1
Q4 - 2024 Earnings $720.0 Million 1/1
Q4 - 2024 Free Cash Flow $811.0 Million 1/1
Trailing 4 Quarters Revenue $19.7 Billion 1/1
Trailing 4 Quarters Earnings $2.0 Billion 1/1
Quarterly Earnings Growth 79% 1/1
Annual Earnings Growth -35% 1/1
Quarterly Revenue Growth 2% 1/1
Annual Revenue Growth 0% 1/1
Cash On Hand $2.9 Billion 1/1
Short Term Debt $1.6 Billion 1/1
Long Term Debt $310.0 Million 1/1

GE HealthCare Technologies Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare GE HealthCare Technologies Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 18.92 1/1
PS 1.92 1/1
PB 4.36 1/1
PC 13.12 1/1
Liabilities to Equity 2.89 1/1
ROA 0.06 1/1
ROE 0.24 1/1
Current Ratio 1.35 1/1
Quick Ratio 0.12 1/1
Long Term Debt to Equity 0.04 1/1
Debt to Equity 0.18 1/1
Burn Rate -9.47 1/1
Cash to Cap 0.08 1/1
CCR 1.13 1/1
EV to EBITDA 33.49 1/1
EV to Revenue 1.85 1/1

Company Details

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

CEO: Mr. Peter J. Arduini

Website: https://www.gehealthcare.com

Address: 500 West Monroe Street Chicago, IL

Exchange: NASDAQ Global Select

Industry: Health Information Services

GE HealthCare Technologies Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to GE HealthCare Technologies Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
GEHC Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 5.3 Billion $720.0 Million
Q3 2024 $ 4.9 Billion $471.0 Million
Q2 2024 $ 4.8 Billion $428.0 Million
Q1 2024 $ 4.7 Billion $374.0 Million
Q4 2023 $ 5.2 Billion $403.0 Million
Q3 2023 $ 4.8 Billion $886.0 Million
Q2 2023 $ 4.8 Billion $707.0 Million
Q1 2023 $ 4.7 Billion $383.0 Million

View All

GEHC Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $2.9 Billion $33.1 Billion $1.5 Billion $8.6 Billion
Q3 2024 $3.6 Billion $33.9 Billion $10.3 Billion $8.5 Billion
Q2 2024 $2.0 Billion $31.9 Billion $9.7 Billion $8.0 Billion
Q1 2024 $2.6 Billion $32.2 Billion $9.7 Billion $7.6 Billion
Q4 2023 $2.5 Billion $32.5 Billion $9.9 Billion $7.3 Billion
Q3 2023 $2.4 Billion $32.4 Billion $10.3 Billion $7.1 Billion
Q2 2023 $1.9 Billion $32.1 Billion $10.2 Billion $7.1 Billion
Q1 2023 $2.3 Billion $32.6 Billion $10.2 Billion $6.7 Billion

View All

GEHC Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 $811.0 Million -$102.0 Million -$679.0 Million
Q3 2024 $648.0 Million -$90.0 Million $1.6 Billion
Q2 2024 -$183.0 Million -$64.0 Million -$549.0 Million
Q1 2024 $274.0 Million -$145.0 Million $59.0 Million
Q4 2023 $956.0 Million -$94.0 Million $86.0 Million
Q3 2023 $570.0 Million -$80.0 Million $475.0 Million
Q2 2023 -$137.0 Million -$70.0 Million -$389.0 Million
Q1 2023 $325.0 Million -$143.0 Million $883.0 Million

View All